This is the last episode of the Biotech Series, and this final episode delves into the emerging field of immuno-oncology in Dubai and the GCC, discussing the development of personalized cancer treatments that activate the immune system to fight cancer, tailored to individuals' genetic makeup.

It outlines the ambitious goals of creating immuno-oncology drugs specifically for the region, addressing the most common cancers, including breast, lung, and colorectal cancer.

The discussion covers drug development challenges, including obtaining funding, integrating with existing healthcare systems, and leveraging AI and government initiatives to speed up the process.

The script highlights the potential of T cell receptor targeted therapeutics and the role of artificial intelligence in drug discovery. Interviews with industry experts emphasize the importance of personalized medicine and the vision of making Dubai a global hub for cutting-edge cancer treatment research and development.

00:00 Introduction to Immuno Oncology in Dubai 00:55 The Battle Against Cancer: Targets and Challenges 02:09 The Journey of Drug Development and Personalized Medicine 02:55 Navigating the Early Stages of Immuno Oncology Projects 04:25 Building a Global Hub for Cancer Research and Treatment 11:57 The Future of TCR Technology and Its Impact on Oncology 18:43 Exploring the Potential of Predictive Oncology and Screening 22:11 Addressing the Challenge of Cancer Treatment Affordability 23:57 Exploring the Costs and Challenges of Cancer Therapy 24:33 The Role of AI in Revolutionizing Cancer Treatment 26:32 Navigating the Complexities of Drug Costs and Healthcare Systems 28:36 The Intricacies of Drug Patents and Their Impact on Innovation 33:40 Personal Journeys: From Clinical Practice to Biotech Innovation 47:12 The Future of Cancer Care: Bringing Cutting-Edge Treatments to Dubai

This podcast episode delves into the intricate world of biotech, focusing on the financial challenges and trends shaping the industry with Dr. James and Dr. Howard, both Oncology Drug Development Physicians.

We discuss the staggering costs of bringing a drug to the market, influenced heavily by the COVID-19 pandemic, which marked a new era for biotech investment and innovation.

Highlighting the transition from small biotech firms to billion-dollar entities almost overnight, the episode explores the subsequent 'golden age' of investment, its decline, and the hurdles small biotech companies face in securing funding amidst a tougher financial landscape marked by increased inflation and interest rates.

The conversation also touches on the funding strategy, the crucial role of venture capital, and the lengthy drug development timeline.

Additionally, Dr James and Dr Howard examine the potential negative impacts on patient care resulting from the industry's consolidation trend, where large pharmaceutical companies acquire smaller biotechs, potentially slowing down innovation.

The episode concludes with discussions on the unique challenges and opportunities within the biotech industry in Dubai, suggesting it as a potential biotech hub due to its supportive government, diverse population, and favorable business environment.

00:00 The Cost of Bringing a Drug to Market: A Deep Dive 00:45 The Biotech Boom: From COVID-19 to Financial Realities 02:36 Venture Capital and the Biotech Funding Dilemma 03:37 The Long Road to Drug Development: Patience and Innovation 05:16 The Impact of Big Pharma on Small Biotech Firms 07:28 Navigating the Complexities of Biotech Innovation 14:44 The Theranos Scandal: A Cautionary Tale in Biotech 25:19 Dubai's Potential as a Biotech Hub: Opportunities and Challenges 31:39 Funding Biotech in Emerging Ecosystems: The UAE Model

In this podcast episode, Doctor James and Doctor Howard, both Oncology Drug Development Physicians, delve into the intricate world of cancer treatment, oncology, and pharmaceuticals, focusing on the challenges and advancements in drug development.

It highlights the pharmaceutical industry's Western-centric nature, the high cost and complexity of developing new drugs, and the regulatory hurdles that slow the process.

The discussion explores how personalized medicine and immunotherapy change the cancer treatment landscape despite the economic and regulatory challenges.

We discuss the potential of non-invasive tests like circulating tumor DNA (ctDNA) in improving cancer diagnosis and treatment.

We also touch on the importance of patient engagement in clinical trials, the evolving role of T cells in cancer defense, and the future of immuno-oncology.

The podcast aims to shed light on the collective effort needed from regulators, pharmaceutical companies, and healthcare professionals to advance cancer treatment and make it more accessible worldwide.